Eisai Announces Completion of Acquisition of Morphotek
Eisai Co., Ltd. and Eisai Corporation of North America announced the completion of Eisai's acquisition of Morphotek® Inc. after having cleared the approval process by the government authorities including the U.S. Federal Trade Commission. The expense for this transaction was US $325 million after excess net cash. Morphotek, based in Exton, Pennsylvania, will continue to be headed by Dr. Nicholas Nicolaides, as President.
Oncology is one of the Eisai's focused areas per defined in the company's 5th mid-term global business plan, the "Dramatic Leap Plan". Eisai currently has an extensive global oncology research program for discovering small molecule anti-cancer agents. This acquisition enables the expansion of Eisai's capabilities into the biologic therapeutics field, with which Eisai will make further contributions to fulfilling a variety of unmet medical needs. In addition, the expansion of Eisai's research & development capability complements the company's establishment of its oncology sales and marketing operations in the U.S.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
